Bionomics was founded in 1991, originally focusing on the development of new treatments in the fields of oncology and women's reproductive health. The company has since expanded to include drug discovery for neurodegenerative and inflammatory disorders. Over the past two decades, Bionomics has developed six compounds that are progressing through clinical development in the US and Europe.
